Advanced pharmacokinetic models based on Organ clearance, circulatory, and fractal concepts

AAPS Journal

Volumn 9, Issue 2, 2007, Pages

  Pang, K Sandy ^a   Weiss, Michael ^b   Macheras, Panos ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Circulatory models; Distribution; Fractal models; Homogeneous; Kidney; Liver; Models; Nonhomogeneous; PBPK; Pharmacokinetic models; Physiologically based pharmacokinetic

Indexed keywords

AMIODARONE; BILE SALT; CALCIUM; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; ENALAPRIL; ESTRADIOL 17 GLUCURONIDE; ESTROGEN SULFOTRANSFERASE; ESTRONE SULFATE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HYDROXYSTEROID SULFOTRANSFERASE; MIBEFRADIL; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 1; SALICYLAMIDE; SULFATASE; SULFOTRANSFERASE;

ARTICLE; CIRCULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESEARCH; DRUG TRANSPORT; ENZYME ACTIVITY; FRACTAL ANALYSIS; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; INTESTINE; LIVER; MICHAELIS MENTEN KINETICS; NONHUMAN; STATISTICAL MODEL;

ANIMALS; BLOOD CIRCULATION; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 34447298122     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0902030     Document Type: Article

References (143)

1. Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 2007;3:235-249.
2. Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973;1:123-136.
3. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cells binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5:625-653.
4. Pang KS, Chiba M. Metabolism: Scaling up from in vitro to organ and whole body. In: Welling PG, Balant LP, eds. Handbook of Experimental Pharmacology. Stuttgart, Germany: Springer-Verlag; 1994:101-187.
5. Liu L, Pang KS. An integrated approach to model hepatic drug clearance. Eur J Pharm Sci. 2006;29:215-230.
6. Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos. 2004;33:1-7.
7. Pang KS, Sun H, Liu S. Interplay between transporters and enzymes. In: Morris ME, You G, eds. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: Wiley and Sons; 2007:709-745.
8. de Lannoy IAM, 3rd, Barker F, 3rd, Pang KS. Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J Pharmacokinet Biopharm. 1993;21:395-422.
9. Sun H, Liu L, Pang KS. Increased estrogen sulfation of estradiol 17β-D glucuronide in rat metastasis tumor livers. J Pharmacol Exp Ther. 2006;319:818-831.
10. Hekman P, van Ginneken CA. Kinetic modeling of the renal excretion of iodopyracet in the dog. J Pharmacokinet Biopharm. 1982;10:77-92.
11. Boom SP, Moons MM, Russel FG. Renal tubular transport of cimetidine in the isolated perfused kidney of the rat. Drug Metab Dispos. 1994;22:148-153.
12. de Lannoy IAM, Hirayama H, Pang KS. A physiological model for renal drug metabolism: enalapril esterolysis to enalaprilat in the isolated perfused rat kidney. J Pharmacokinet Biopharm. 1990;18:561-587.
13. Doherty M, Pang KS. Route dependent metabolism of morphine in the vascularly perfused rat intestine preparation. Pharm Res. 2000;17:291-297.
14. Cong D, Doherty M, Pang KS. A new physiologically-based segregated flow model to explain route-intestinal metabolism. Drug Metab Dispos. 2000;28:224-235.
15. Benowitz N, Forsyth FP, Melmon KL, et al. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther. 1974;16:87-98.
16. Jarnberg J, Johanson G. Physiologically based modeling of 1,2,4-trimethylbenzene inhalation toxicokinetics. Toxicol Appl Pharmacol. 1999;155:203-214.
17. Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab. 2005;6:309-328.
18. Tirona RG, Kim RB. Nuclear receptor and drug disposition gene regulation. J Pharm Sci. 2005;94:1169-1186.
19. Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys. 2005;433:397-412.
20. Sirianni GL, Pang KS. Organ clearance concepts: new perspectives on old principles. J Pharmacokinet Biopharm. 1997;25:449-470.
21. Gillette JR. Factors affecting drug metabolism. Ann N Y Acad Sci. 1971;179:43-66.
22. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377-390.
23. Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J. 1998;55:413-421.
24. Jungermann K. Zonation of metabolism and gene expression in liver. Histochem Cell Biol. 1995;103:81-91.
25. Baron J, Redick HA, Guengerich FP. Immunohistochemical study on the localization and distributions of phenobarbital- and 3-methylcholanthrene-inducible cytochromes P-450 within the livers of untreated rats. J Biol Chem. 1981;256:5931-5937.
26. Knapp SA, Green MD, Tephly TR, et al. Immunohistochemical demonstration of isozyme- and strain-specific differences in the intralobular localizations and distributions of UDP-glucuronosyltransferases in livers of untreated rats. Mol Pharmacol. 1988;33:14-21.
27. Tosh D, Borthwick EB, Sharp S, et al. Heterogeneous expression of sulphotransferases in periportal and perivenous hepatocytes prepared from male and female rat liver. Biochem Pharmacol. 1996; 51:369-374.
28. Homma H, Tada M, Nakamura T, et al. Heterogeneous zonal distributon of sulfotransferase isoenzymes in rat liver. Arch Biochem Biophys. 1997;339:235-241.
29. Tan E, Pang KS. Sulfation is rate-limiting in the futile cycling between estrone and estrone sulfate in enriched periportal and perivenous rat hepatocytes. Drug Metab Dispos. 2001;29:335-346.
30. Tirona RG, Pang KS. Bimolecular glutathione conjugation of ethacrynic acid and efflux of the glutathione adduct by periportal and perivenous rat hepatocytes. J Pharmacol Exp Ther. 1999;290:1230-1241.
31. Anundi IM, Kauffman FC, el-Mouelhi M, et al. Hydrolysis of organic sulfates in periportal and pericentral regions of the liver lobule: studies with 4-methylumbelliferyl sulfate in the perfused rat liver. Mol Pharmacol. 1986;29:599-605.
32. +/taurocholate cotransporting polypeptide in rat liver. Gastroenterology. 1994;107:1781-1787.
33. Abu-Zahra TN, Wolkoff AW, Kim RB, et al. Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Melab Dispos. 2000;28:801-806.
34. Liu L, Mak E, Tirona RG, et al. Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver. J Pharmacol Exp Ther. 2005;315:433-448.
35. Reichel C, Gao B, van Montfoort J, et al. Localizatoin and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology. 1999;117:688-695.
36. Cattori V, van Montfoort JE, Stieger B, et al. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001;443:188-195.
37. Meyer-Wentrup F, Karbach U, Gorboulev V, et al. Membrane localization of the electrogeneic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun. 1998;248:673-678.
38. Gerloff T, Stieger B, Hangenbuch B, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998;273:10046-10050.
39. Donner MG, Warskulat U, Saha N, Häussinger D. Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biol Chem. 2004;385:331-339.
40. Rappaport AM. The structural and functional unit in the human liver (liver acinus). Anat Rec. 1958;130:673-689.
41. Abu-Zahra TN, Pang KS. Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metab Dispos. 2000;28:807-813.
42. Tirona R, Pang KS. Sequestered endoplasmic reticulum space for sequential metabolism of salicylamide: coupling of hydroxylation and glucuronidation. Drug Metab Dispos. 1996;24:821-833.
43. Xu X, Tang BK, Pang KS. Sequential metabolism of salicylamide exclusively to gentisamide-5-glucuronide and not gentisamide sulfate conjugates in single pass in situ perfused rat liver. J Pharmacol Exp Ther. 1990;253:963-973.
44. Doherty M, Poon K, Tsang C, et al. Transport is not rate-limiting in morphine glucuronidation in the single pass perfused rat liver preparation. J Pharmacol Exp Ther. 2006;317:890-900.
45. Tan E, Lu T, Pang KS. Futile cycling of estrone sulfate and estrone in the recirculating, perfused rat liver. J Pharmacol Exp Ther. 2001;297:423-436.
46. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (Gillette Review Series). Drug Metab Dispos. 2003;31:1507-1519.
47. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60:14-24.
48. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283:1552-1562.
49. Li LY, Amidon GL, Kim JS, et al. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability. J Pharmacol Exp Ther. 2002;301:586-593.
50. Koster AS, Frankhuijzen-Sierevogel AC, Noordhoek J. Glucuronidation of morphine and six β2-sympathominetics in isolated rat intestinal epithelial cells. Drug Metab Dispos. 1985;13:232-237.
51. Schwarz LR, Schwenk M. Sulfation in isolated enterocytes of guinea pig: dependence of inorganic sulfate. Biochem Pharmacol. 1984;33:3353-3356.
52. Pinkus LM, Ketley JN, Jakoby WB. The glutathione S-transferases as a possible detoxification system of rat intestinal epithelium. Biochem Pharmacol. 1977;26:2359-2363.
53. Huijghebaert SM, Sim SM, Back DJ, et al. Distribution of estrone sulfatase activity in the intestine of germfree and conventional rats. J Steroid Biochem. 1984;20:1175-1179.
54. Fei YJ, Kanai Y, Nussberger S, et al. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 1994;368:563-566.
55. Wong MH, Oelkers P, Craddock AL, et al. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem. 1994;269:1340-1347.
56. Shneider BL, Dawson PA, Christie DM, et al. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J Clin Invest. 1995;95:745-754.
57. Cong D, Fong AKY, Lee R, et al. Absorption of benzoic acid (BA) by segmental regions of the in situ perfused rat small intestine. Drug Metab Dispos. 2001;29:1539-1547.
58. 3 on transporters and enzymes associated with bile acid homeostasis in rat liver [abstract]. AAPSJ. 2005;S2:.
59. Liu S, Tam D, Chen X, Pang KS. An unstirred water layer and P-glycoprotein barring digoxin absorption by the perfused rat small intestine preparation: Induction studies with and without pregnenolone 16α-carbonitrile (PCN) induction. Drug Metab Dispos. 2006;34:1468-1479.
60. Mottino AD, Hoffman T, Jennes L, et al. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther. 2000;293:717-723.
61. Gotoh Y, Suzuki H, Kinoshita S, et al. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/ multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther. 2000;292:433-439.
62. Rost D, Mahner S, Sugiyama Y, et al. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol. 2002;282:G720-G726.
63. Tam D, Tirona RG, Pang KS. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos. 2003;31:373-383.
64. Matsubara T, Kim HJ, Shimada M, et al. Isolation and characterization of a new major intestineal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther. 2004;309:1282-1290.
65. Cutler DJ. A linear recirculation model for drug disposition. J Pharmacokinet Biopharm. 1979;7:101-116.
66. Weiss M, Förster W. Pharmacokinetic model based on circulatory transport. Eur J Clin Pharmacol. 1979;16:287-293.
67. Weiss M. Pharmacokinetics in organs and the intact body: model validation and reduction. Eur J Pharm Sci. 1999;7:119-127.
68. Krejcie TC, Avram MJ. What determines anesthetic induction dose, It's the front-end kinetics, doctor! Anesth Analg. 1999;89:541-544.
69. Upton RN, Ludbrook GL, Grant C, Martinez AM. Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. Anesth Analg. 1999;89:545-552.
70. Krejcie TC, Avram MJ, Gentry WB, et al. A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. J Pharmacokinet Biopharm. 1997;25:169-190.
71. Krejcie TC, Wang Z, Avram MJ. Drug-induced hemodynamic perturbations alter the disposition of markers of blood volume, extracellular fluid, and total body water. J Pharmacol Exp Ther. 2001;296:922-930.
72. Avram MJ, Krejcie TC, Henthorn TK. The concordance of early antipyrine and thiopental distribution kinetics. J Pharmacol Exp Ther. 2002;302:594-600.
73. Krejcie TC, Henthorn TK, Gentry WB, et al. Modifications of blood volume alter the disposition of markers of blood volume, extracellular fluid, and total body water. J Pharmacol Exp Ther. 1999;291:1308-1316.
74. Kuipers JA, Boer F, Olofsen E, et al. Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. Anesthesiology. 2001;94:47-55.
75. Upton RN, Ludbrook GL. A physiologically based, recirculatory model of the kinetics and dynamics of propofol in man. Anesthesiology. 2005;103:344-352.
76. Upton RN, Grant C, Martinez AM, et al. Recirculatory model of fentanyl disposition with the brain as the target organ. Br J Anaesth. 2004;93:687-697.
77. Weiss M. Errors in clearance estimation after bolus injection and arterial sampling: non-existence of a central compartment. J Pharmacokinet Biopharm. 1997;25:255-260.
78. Weiss M, Roberts MS. Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: application of a stochastic model to the rat hindlimb. J Pharmacokinet Biopharm. 1996;24:173-196.
79. Upton RN. The two-compartment recirculatory pharmacokinetic model - an introduction to recirculatory pharmacokinetic concepts. Br J Anaesth. 2004;92:475-484.
80. Weiss M, Pang KS. The dynamics of drug distribution. I. Role of the second and third curve moment. J Pharmacokinet Biopharm. 1992;20:253-278.
81. Weiss M. A note on the role of generalized inverse Gaussian distributions of circulatory transit times in pharmacokinetics. J Math Biol. 1984;20:95-102.
82. Weiss M, Krejcie TC, Avram MJ. Transit time dispersion in the pulmonary and systemic circulation: effects of cardiac output and solute diffusivity. Am J Physiol. 2006;291:H861-H870.
83. Roberts MS, Anissimov YG, Weiss M. Commentary: Using the convection-dispersion model and transit time density functions in the analysis of organ distribution kinetics. J Pharm Sci. 2000;89:1579-1586.
84. Oliver RE, Jones AF, Rowland M. A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J Pharmacokinet Pharmacodyn. 2001;28:27-55.
85. Karalis V, Dokoumetzidis A, Macheras P. A physiologically based approach for the estimation of recirculatory parameters. J Pharmacol Exp Ther. 2003;308:198-205.
86. Weiss M, Hübner GH, Hübner IG, Teichmann W. Effects of cardiac output on disposition kinetics of sorbitol: recirculatory modelling. Br J Clin Pharmacol. 1996;41:261-268.
87. Weiss M, Krejcie TC, Avram MJ. Circulatory transport and capillary-tissue exchange as determinants of the distribution kinetics of inulin and antipyrine in dog. J Pharm Sci. 2007;96:913-926.
88. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T. Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res. 1995;12:880-883.
89. 13N]ammonia kinetics in hepatic PET experiments: A minimal recirculatory model. Eur J Nucl Med. 2002;29:1648-1656.
90. Ben-Avraham D, Havlin S. Diffusion and Reactions in Fractals and Disordered Systems. New York, NY: Cambridge University Press; 2000.
91. Bassingthwaighte JB, Liebovitch LS, West BJ. Fractal Physiology. New York, NY: Oxford University Press; 1994.
92. Kopelman R. Fractal reaction kinetics. Science. 1988; 241:1620-1626.
93. Macheras P, Iliadis A. Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics: Homogeneous and Heterogeneous Approaches. New York, NY: Springer, 2006.
94. Dokoumetzidis A, Karalis V, Iliadis A, et al. The heterogeneous course of drug transit through the body. Trends Pharmacol Sci. 2004;25:140-146.
95. Nittmann J, Daccord G, Stanley H. Fractal growth of viscous fingers -quantitative characterization of a fluid instability phenomenon. Nature. 1985;314:141-144.
96. VanDamme H. Flow and interfacial instabilities in Newtonian and colloidal fluids (or the birth, life and death of a fractal), The Fractal Approach to Heterogeneous Chemistry. Chichester, UK: Wiley; 1989.
97. Bhaskar K, Garik P, Turner B, et al. Viscous fingering of HCl through gastric mucin. Nature. 1992;360:458-461.
98. Holm L, Flemstrom G. Microscopy of acid transport at the gastric surface in vivo. J Intern Med Suppl. 1990;732:91-95.
99. Macheras P, Argyrakis P. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm Res. 1997;14:842-847.
100. Caroli-Bosc F, Iliadis A, Salmon L, et al. Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients. Fundam Clin Pharmacol. 2000;14:601-609.
101. Higaki K, Yamashita S, Amidon G. Time-dependent oral absorption models. J Pharmacokinet Pharmacodynam. 2001;28:109-128.
102. Kalampokis A, Argyrakis P, Macheras P. Heterogeneous tube model for the study of small intestinal transit flow. Pharm Res. 1999; 16:87-91.
103. Kalampokis A, Argyrakis P, Macheras P. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. Pharm Res. 1999;16:1764-1769.
104. Wang Z, Zhenya H, Chen J. Chaotic behavior of gastric migrating myoelectrical complex. Biomed Engr. 2004;51:1401-1406.
105. Weibull W. A statistical distribution of wide applicability. J Appl Mech. 1951;18:293-297.
106. Macheras P, Dokoumetzidis A. On the heterogeneity of drug dissolution and release. Pharm Res. 2000;17:108-112.
107. Lansky P, Weiss M. Does the dose-solubility ratio affect the mean dissolution time of drugs? Pharm Res. 1999;16:1470-1476.
108. Lansky P, Weiss M. Modeling heterogeneity of properties and random effects in drug dissolution. Pharm Res. 2001;18:1061-1067.
109. Lansky P, Weiss M. Classification of dissolution profiles in terms of fractional dissolution rate and a novel measure of heterogeneity. J Pharm Sci. 2003;92:1632-1647.
110. Dokoumetzidis A, Macheras P. A population growth model of dissolution. Pharm Res. 1997;14:1122-1126.
111. Valsami G, Dokoumetzidis A, Macheras P. Modeling of supersaturated dissolution data. Int J Pharm. 1999;181:153-157.
112. Bunde A, Havlin S, Nossal R, Stanley HE, Weiss GH. On controlled diffusion-limited drug release from a leaky matrix. J Chem Phys. 1985;83:5909-5913.
113. Kosmidis K, Argyrakis P, Macheras P. A reappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function. Pharm Res. 2003;20:988-995.
114. Kosmidis K, Argyrakis P, Macheras P. Fractal kinetics in drug release from finite fractal matrices. J Chem Phys. 2003;119:6373-6377.
115. Villalobos R, Vidales AM, Cordero S, Quintanar D, Domnguez A. Monte Carlo simulation of diffusion-limited drug release from finite fractal matrices. J Sol-Gel Sci Technol. 2006;37:195-199.
116. Villalobos R, Ganem A, Cordero S, et al. Effect of the drug-excipient ratio in matrix-type-controlled realease systems: computer simulation study. Drug Dev Ind Pharm. 2005;31:535-543.
117. Haddish-Berhane N, Nyquist C, Haghighi K, et al. A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems. J Control Release. 2006;110:314-322.
118. Barat A, Ruskin HJ, Crane M. Probabilistic models for drug dissolution. Part I. Review of Monte Carlo and stochastic cellular automata approaches. Simul Model Pract Th. 2006;14:834-856.
119. Barat A, Ruskin HJ, Crane M. Probabilistic methods for drug dissolution. Part 2. Modelling a soluble binary drug delivery system dissolving in vitro. Simul Model Pract Th. 2006;14:857-873.
120. Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 2006;309:44-50.
121. West G, Brown J, Enquist B. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122-126.
122. West GB, Brown J, Enquist B. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284:1677-1679.
123. Karalis V, Claret L, Iliadis A, Macheras P. Fractal volume of drug distribution: it scales proportionally to body mass. Pharm Res. 2001;18:1056-1060.
124. 18F]FDG PET imaging: the "body surface area" may be a volume, Phys Med Biol. 2006;51:N47-N50.
125. Karalis V, Macheras P. Drug disposition viewed in terms of the fractal volume of distribution. Pharm Res. 2002;19:697-704.
126. Karalis V, Tsantili A, Macheras P. Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics. Pharm Res. 2002;19:1829-1836.
127. Karalis V, Tsantili A, Macheras P. Quantitative structure pharmacokinetic relationships for disposition parameters of cephalosporins. Eur J Pharm Sci. 2003;20:115-123.
128. Dokoumetzidis A, Macheras P. A tube model for transport and dispersion in the circulatory system based on the vascular fractal tree. Ann Biomed Eng. 2003;31:284-293.
129. Claret L, Iliadis A, Macheras P. A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin. J Pharmacokinet Pharmacodyn. 2001;28:445-463.
130. Rescigno A. The rise and fall of compartmental analysis. Pharmacol Res. 2001;44:337-342.
131. Wise ME, Borsboom JM. Two exceptional sets of physiological clearance curves and their mathematical form: test cases? Bull Math Biol. 1989;51:579-596.
132. Matis JH, Wehrly TE. A general approach to non-Markovian compartmental models. J Pharmacokinet Biopharm. 1998;26:437-456.
133. Weiss GH, Goans RE, Gitterman M, Abrams SA, Vieira NE, Yergey AL. A non-Markovian model for calcium kinetics in the body. J Pharmacokinet Biopharm. 1994;22:367-379.
134. Macheras P. A fractal approach to heterogeneous drug distribution: calcium pharmacokinetics. Pharm Res. 1996;13:663-670.
135. Weiss M. The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J Pharmacokinet Biopharm. 1999;27:383-396.
136. López-Quintela M, Casado J. Revision of the methodology in enzyme kinetics: a fractal approach. J Theor Biol. 1989;139:129-139.
137. Savageau MA. Michaelis-Menten mechanism reconsidered: implications of fractal kinetics. J Theor Biol. 1995;176:115-124.
138. Savageau MA. Development of fractal kinetic theory for enzyme-catalysed reactions and implications for the design of biochemical pathways. Biosystem. 1998;47:9-36.
139. Berry H. Monte Carlo simulations of enzyme reactions in two dimensions: fractal kinetics and spatial segregation. Biophys J. 2002;83:1891-1901.
140. Fuite J, Marsh R, Tuszynski J. Fractal pharmacokinetics of the drug mibefradil in the liver. Phys Rev E. 2002;66:21904.
141. Kosmidis K, Karalis V, Argyrakis P, et al. Michaelis Menten kinetics under spatially constrained conditions: application to mibefradil pharmacokinetics. Biophys J. 2004;87:1498-1506.
142. Marsh R, Tuszynski JA. Fractal Michaelis-Menten kinetics under steady state conditions: application to mibefradil. Pharm Res. 2006;23:2760-2767.
143. Chelminiak P, Dixon JM, Tuszynski JA, et al. Application of a random network with a variable geometry of links to the kinetics of drug elimination in healthy and diseased livers. Phys Rev E. 2006;5:51912.